Vector processing and materials

CELL AND GENE THERAPY INSIGHTS

April 2024

Vector processing and materials

Download PDF

Expert Insight

Are we there yet? After 250+ AAV-based clinical trials, do we have a well-paved road toward first-in-human entry?

Are we there yet? After 250+ AAV-based clinical trials, do we have a well-paved road toward first-in-human entry?

Long Chen, Chia Chu, Francesca Vitelli

Improving process efficiency to reduce cost-of-goods per dose in manufacturing of recombinant AAVs

Improving process efficiency to reduce cost-of-goods per dose in manufacturing of recombinant AAVs

G Thakur, S Mink, H Bak et al.

Innovator Insight

Accelerating AAV process development with a PAT-driven TFF system

Accelerating AAV process development with a PAT-driven TFF system

AAV capsids separation is critical for advancing gene therapies

AAV capsids separation is critical for advancing gene therapies

Timotej Žvanut, Andreja Gramc Livk, Aleš Štrancar

Trends in innovation for downstream process intensification, product yield, single use closed systems, and gentle ATMP bioprocessing: a KOL panel discussing 2024 insights in gene therapy manufacturing

Trends in innovation for downstream process intensification, product yield, single use closed systems, and gentle ATMP bioprocessing: a KOL panel discussing 2024 insights in gene therapy manufacturing

Rachel Legmann, Andrew D Tustian

Expediting development and manufacturing of advanced therapies: critical starting materials case studies

Expediting development and manufacturing of advanced therapies: critical starting materials case studies

Commentary

Combining best practices and analytical reference materials to tackle challenges in AAV manufacturing

Combining best practices and analytical reference materials to tackle challenges in AAV manufacturing

FastFacts

Accelerate time to clinic for advanced therapies with a platform approach

Accelerate time to clinic for advanced therapies with a platform approach

John Lee, Cédrick Rousseaux, Dana Cipriano

Viewpoint

Best practices and considerations for outsourcing with CDMOs

Best practices and considerations for outsourcing with CDMOs

Joseph W Graskemper

Interview

Challenges and benefits in harnessing platform processes for viral vector manufacture

Challenges and benefits in harnessing platform processes for viral vector manufacture

Scott Cross, Christina Fuentes, Jacob Staudhammer

Delivering on a vision of a digitally enabled future for viral vector manufacturing

Delivering on a vision of a digitally enabled future for viral vector manufacturing

Sönke Brunswieck, Tania Chilima

Harnessing producer cell lines and process intensification to address the AAV process productivity conundrum

Harnessing producer cell lines and process intensification to address the AAV process productivity conundrum

Webinars

Expediting development and manufacture of advanced therapies: critical starting materials case study

Expediting development and manufacture of advanced therapies: critical starting materials case study

Andrew Frazer

Increasing efficiency in AAV-based gene therapy production: platform optimization with multiserotype AAV affinity capture

Increasing efficiency in AAV-based gene therapy production: platform optimization with multiserotype AAV affinity capture

Nicolas Laroudie, Tiago Albano

Commercial-scale manufacture of lentivirus for ex vivo and in vivo therapies

Commercial-scale manufacture of lentivirus for ex vivo and in vivo therapies

Rachel Legmann, Michelle Yen Tran

Alternative solutions to separate AAV full and empty capsids using anion exchange

Alternative solutions to separate AAV full and empty capsids using anion exchange

Åsa Hagner-McWhirter, Mark Schofield

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes

It’s a match: cell line engineering for AAV manufacturing expands the options for therapeutic programs

It’s a match: cell line engineering for AAV manufacturing expands the options for therapeutic programs

Dovilé Woods